• In early May 2026, Capricor Therapeutics filed a lawsuit against Nippon Shinyaku and NS Pharma seeking to rescind their 2022 U.S. distribution agreement for Deramiocel, alleging pricing flaws and inadequate commercial launch preparations that could restrict patient access to the Duchenne muscular dystrophy therapy.
• This legal move puts the spotlight on how Capricor plans to control Deramiocel’s commercialization pathway at a critical point in its FDA review and potential future market entry.
• Next, we’ll examine how Capricor’s attempt to regain Deramiocel distribution rights may reshape the company’s investment narrative and risk profile.

Invest in the nuclear renaissance through our list of 91 elite nuclear energy infrastructure plays powering the global AI revolution.

Capricor Therapeutics Investment Narrative Recap

To own Capricor today, you have to believe Deramiocel can clear its FDA review and eventually support a sustainable commercial business, despite zero current product revenue and mounting losses. The lawsuit with Nippon Shinyaku adds legal and launch uncertainty, but it does not alter the key near term catalyst, which remains the August 22, 2026 PDUFA decision. The biggest current risk is that any regulatory setback would prolong losses and pressure Capricor’s funding options.

The recent Phase 3 HOPE 3 data release is especially relevant here, as it underpins the ongoing BLA review while this distribution dispute unfolds. Capricor reported that Deramiocel slowed disease progression on multiple functional and cardiac measures, and the FDA has resumed its review after lifting the prior complete response letter. How regulators ultimately weigh this dataset will matter far more to the story than the short term share reaction to the lawsuit.

Yet despite this progress, investors should be aware that the lawsuit and Capricor’s cash burn could still...

Capricor Therapeutics’ narrative projects $245.5 million revenue and $109.6 million earnings by 2029.

Uncover how Capricor Therapeutics' forecasts yield a $54.67 fair value, a 71% upside to its current price.

Exploring Other Perspectives

Some of the lowest ranked analysts take a far more cautious view, assuming roughly US$68.3 million of revenue and only US$11.1 million of earnings by 2028, so if you worry about delayed approvals and cash constraints, their narrative highlights how much more conservative expectations can be compared with the current focus on Deramiocel’s Phase 3 data and the fresh uncertainty around its U.S. launch partner.

Explore 7 other fair value estimates on Capricor Therapeutics - why the stock might be worth over 9x more than the current price!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Capricor Therapeutics research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Capricor Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Capricor Therapeutics' overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• Rare earth metals are the new gold rush. Find out which 33 stocks are leading the charge.
• Capitalize on the AI infrastructure supercycle with our selection of the 38 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.